Health
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma – Newswise
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy, which…
-
Business22 hours agoForget CBA and buy these high-yield ASX dividend shares
-
General22 hours agoUK PM ready to ‘shelter’ businesses from tariff storm
-
General22 hours agoWhy do states and territories have different school holidays?
-
General24 hours agoEat the problem: sea urchin pest-to-plate funding urged